Longer duration of HBV-active antiretroviral Therapy is linked to favorable virological outcome in HIV-HBV co-infected patients

HIV Clinical Trials

Volumn 10, Issue 3, 2009, Pages 153-159

  Lee, Tsan ^a   Núñez, Marina ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Alanine aminotransferase (ALT); Cirrhosis; HBV; Hepatocellular carcinoma (HCC); HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ACADEMIC MEDICAL CENTERS; ADULT; AFRICAN AMERICANS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORTH CAROLINA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 69249148630     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1003-153     Document Type: Article

References (26)

1. Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. 2005;5:374-382.
2. Shire NJ, Sherman KE. Management of HBV/HIV-coinfected patients. Semin Liver Dis. 2005;25(Suppl 1):48-57.
3. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(1 Suppl):S65-70.
4. Thio C, Locarnini S. Treatment of HIV/HBV co-infection: clinical and virological issues. AIDS Rev. 2007;9:40-53.
5. Núñez M, Belen R, Diaz-Pollan B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retrovirus. 2006;22:842-848.
6. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis. 2007;45:624-632.
7. Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45:1221-1229.
8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171.
9. Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003;125:444-451.
10. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002; 29(Suppl 1):S2-10.
11. Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Munoz A, Thomas DL, Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet. 2002;360:1921-1926.
12. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the longterm outcome of chronic hepatitis B. Gastroenterology. 2002;123:1812-1822.
13. Bonacini M, Bzowej N, Louie S, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C. AIDS. 2004;18:2039-2045.
14. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38:1471-1477.
15. Konopnicki D, Mocroft A, de Wit S. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:2117-2125.
16. Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)- specifi c T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005;191:1169-1179.
17. Wursthorn K, Buggisch P, Lutgehetmann M, Zollner B, Petersen J. Temporary HBV resolution in an HIV-co-infected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther. 2006;11:647-652.
18. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS. 2007;21:771-774.
19. Bräu N, Fox RK, Xiao P. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study. J Hepatol. 2007;47:527-537.
20. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. REVEALHBV Study Group. Gastroenterology. 2006;130:678-686.
21. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539.
22. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18(15):2039-2045.
23. Peters MG. Diagnosis and management of hepatitis B virus and HIV coinfection. Top HIV Med. 2007;15:163-166.
24. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008;197(Suppl 3):S279-S293.
25. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008; 22:1399-1410.
26. Iser DM, Sasadeusz J. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol. 2008;23:699-706.